A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
Latest Information Update: 18 May 2025
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Familial adenomatous polyposis; Intestinal polyps
- Focus Therapeutic Use
Most Recent Events
- 13 Apr 2024 Planned End Date changed from 31 Jan 2026 to 21 Feb 2026.
- 23 Nov 2023 Planned number of patients changed from 60 to 80.
- 23 Nov 2023 Planned End Date changed from 21 Feb 2026 to 31 Jan 2026.